For the detailed pathways see (Fig. 5c, d, Supplementary Table 6C, D): Regulation of actin cytoskeleton (F:p = 0.001,q = 0.02; M:p = 0.0004,q = 0.09), Proteoglycans in cancer (F:p = 7.6E-05,q = 0.01; M:p = 0.002,q = 0.16), ECM-receptor interaction (F:p = 0.001,q = 0.02; M:p = 0.007,q = 0.26), Hippo signaling (F:p = 0.0004,q = 0.02; M:p = 0.01,q = 0.27), and PI3K-Akt signaling (F:p = 0.0009,q = 0.02; M:p = 0.02,q = 0.38). This evidence concerns the gene AKT1 and cancer.